Synthesis and evaluation of a ligand targeting the μ and δ opioid receptors for drug delivery to lung cancer.

Guo Li, Philip S Low

Open access · greenAbstract read

In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.7field-weighted citation impact, top 32% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

Design, synthesis and evaluation ofNuclear medicine and biology · 2019
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Guo LiDepartment of Chemistry, Purdue University, 720 Clinic Drive, West Lafayette 47907, USA.

Philip S LowDepartment of Chemistry, Purdue University, 720 Clinic Drive, West Lafayette 47907, USA.

Purdue University West Lafayette · US

Funding

Transgenic Mouse Core Facility Shared Resource (TMCF-SR)P30CA023168 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI Andrea L Kasinski · 1985 to 2026

$43.4M

NCI NIH HHS P30 CA023168

6 · The paper itself

Abstract

A well-established approach to developing new imaging agents and treatments for cancer begins with the recognition of receptors that are overexpressed in cancer cells. Ideally, these same receptors would also be absent, or minimally expressed, in healthy tissue. The mu (μ) and delta (δ) opioid receptors (MOR and DOR respectively) match these criteria, with expression in cancer cells that is higher than primary lung epithelial cells. Naltrexone is a drug approved by the U.S. Food and Drug Administration (FDA) for treatment of alcohol dependence or prevention of relapse from opioid addiction. Since naltrexone binds with high affinity to both MOR and DOR, it was selected as the platform for development of novel ligands capable of delivering a cytotoxic payload to non-small cell lung cancer (NSCLC). This study outlines the synthesis of two ligands, with peptide or PEG linkers that were synthesized from 6-amino-naltrexone and conjugated with rhodamine dye or

Indexed as

Drug Delivery SystemsAnimalsCarcinoma, Non-Small-Cell LungDrug CarriersHEK293 CellsHumansLigandsLung NeoplasmsMiceModels, MolecularNaltrexoneNarcotic AntagonistsReceptors, Opioid, deltaReceptors, Opioid, muTissue DistributionDrug CarriersLigandsNaltrexoneNarcotic AntagonistsReceptors, Opioid, deltaReceptors, Opioid, muLung cancerNaltrexoneSmall-molecule drug conjugate

Identifiers

PMID28291693

DOI10.1016/j.bmcl.2016.06.067

PMCPMC5771650

OpenAlexW2461438357

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.